In Reply-Reference-Cited by-同舟云学术

In Reply

Published:2020-11-23 Issue:1 Volume:26 Page:e192-e193
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Gubbi Sriram¹,Cordes Lisa M.²,Klubo-Gwiezdzinska Joanna¹,Madan Ravi A.²,Nieman Lynnette K.³,Gulley James L.⁴,Del Rivero Jaydira⁵

Affiliation:

1. Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

2. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

3. Diabetes, Endocrine, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

4. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

5. Developmental Therapeutics Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA

Abstract

This letter to the editor responds to comments by Salinas and colleagues on experiences with identification of adrenal insufficiency among patients on immune checkpoint inhibitor therapy.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/onco.13589

Reference10 articles.

1. Primary adrenal insufficiency due to immune checkpoint inhibitors: More common than we thought;Salinas;The Oncologist,2020

2. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors;de Filette;Horm Metab Res,2019

3. Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation;Gubbi;Best Pract Res Clin Endocrinol Metab,2019

4. Hypophysitis secondary to cytotoxic T-lymphocyte–associated protein 4 blockade: Insights into pathogenesis from an autopsy series;Caturegli;Am J Pathol,2016

5. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints;Chang;Endocr Rev,2019